C

Concord Biotech Ltd
NSE:CONCORDBIO

Watchlist Manager
Concord Biotech Ltd
NSE:CONCORDBIO
Watchlist
Price: 2 019.3 INR 1.41% Market Closed
Market Cap: 211.3B INR
Have any thoughts about
Concord Biotech Ltd?
Write Note

Concord Biotech Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Concord Biotech Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
C
Concord Biotech Ltd
NSE:CONCORDBIO
Cash from Operating Activities
â‚ą2.7B
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Cash from Operating Activities
â‚ą45.4B
CAGR 3-Years
8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Cash from Operating Activities
â‚ą45B
CAGR 3-Years
7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cash from Operating Activities
â‚ą127.2B
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Cash from Operating Activities
â‚ą34.1B
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Cash from Operating Activities
â‚ą21.5B
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Concord Biotech Ltd
Glance View

Market Cap
211.3B INR
Industry
Pharmaceuticals

Concord Biotech Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2023-08-18. Concord Biotech Limited is an India-based research and development driven biopharma company. The firm is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The firm manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic processes and finished formulations. The company manufactures fermentation and semi-synthetic based products in the therapeutic segments, such as immunosuppressants, anti-bacterial, oncology, anti-fungal and others. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Vancomycin Hydrochloride, Micafungin Sodium, Mupirocin, Romidepsin, Dactinomycin, and Pravastatin Sodium, among others. The company also has a pipeline of API products under development. Its API products under development include Polymyxin B, Fidaxomicin, Doxorubicin, and others. The firm provides products in the critical care, immunology, nephrology, and transplant medicine segments.

CONCORDBIO Intrinsic Value
1 104.97 INR
Overvaluation 45%
Intrinsic Value
Price
C

See Also

What is Concord Biotech Ltd's Cash from Operating Activities?
Cash from Operating Activities
2.7B INR

Based on the financial report for Mar 31, 2024, Concord Biotech Ltd's Cash from Operating Activities amounts to 2.7B INR.

What is Concord Biotech Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
17%

Over the last year, the Cash from Operating Activities growth was 8%. The average annual Cash from Operating Activities growth rates for Concord Biotech Ltd have been 17% over the past three years .

Back to Top